Go to Sitemap
The Garron Family Cancer Centre's Faculty
The Garron Family Cancer Centre (GFCC) is an innovative and collaborative virtual centre that brings together scientists, clinicians, and educators across multiple disciplines to advance the diagnosis, treatment and outcomes of children, adolescents and young adults with cancer. GFCC faculty is far-reaching and its collaborators can be found throughout numerous divisions, departments and programs within the Hospital, Research Institute and the broader community.
SickKids Foundation
- Ulana Bochnewicz
Clinical Advisory Council
Education Advisory Council
- Michael Wilson, PhD (Co-Chair)
- Denise Mills, NP (Co-Chair)
Fellowship Advisory Council
- Kathryn Breckbill
- Donna Berry
- Devon Williams (Interim)
Associated departments and divisions
- Department of Diagnostic Imaging
- Department of General Surgery
- Department of Neurosurgery
- Department of Orthopaedic Surgery
- Department of Pathology and Laboratory Medicine
- Department of Radiation Oncology
- Department of Urology
- Labatt Brain Tumor Research Centre
- Division of Haematology/Oncology
- Blood & Marrow Transplantation & Cellular Therapy
- Haematology
- Leukemia/Lymphoma
- Neuro-oncology
- Solid Tumor
- Cancer Genetics Program
Milestones and achievements
These milestones are just a handful of projects from the GFCC that are making an impact in cancer research and treatment.
KiCS/PROFYLE
In 2016, SickKids established the world-leading SickKids Cancer Sequencing (KiCS) Program, which was designed to analyze the genetic make-up of a child’s cancer to determine a patient’s unique genetic fingerprint, identify the cause of the tumor, gain information about prognosis, and implement personalized treatments. Together with PROFYLE, a trailblazing pan-Canadian program being conducted in partnership with the Terry Fox Research Institute, multiple childhood cancer foundcations, and all 16 paediatric cancer programs across Canada, KiCS matches nationally-collected sequencing data with potentially life-saving drugs.
CAR T-cell therapy
CAR T-cell therapy, a treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to the cancer cells and kill them, was first approved for use by Health Canada was in 2018. CAR T-cell therapy is now available for patients at SickKids with recurrent or refractory childhood acute lymphoblastic leukemia (ALL). SickKids is one of only 2 Canadian centres to offer CAR T-cell therapy for relapsed ALL. To date, over 419 cancer patients from SickKids, other centres in Ontario and Canada and internationally, have been enrolled in KiCS, with clinically relevant mutations found in almost 53% of cases.
New Agent and Innovative Therapy (NAIT) program
The New Agent and Innovative Therapy program (NAIT) at SickKids is supported in part by the GFCC and is focused on providing access to new drugs and other treatments for childhood cancer patients. For more information about current clinical trials and eligibility, contact us today.
MIBG Program
To deliver this targeted radiation safely to children, and to keep families and hospital staff safe, a specialized room, equipment and healthcare team with special training are needed. SickKids' MIBG room includes state-of-the-art equipment and specialized Neuroblastoma and MIBG Therapy Programs.
